HuvePharma Reports Ivermectin Helps Fight Against COVID-19 in Randomized, Controlled, Double-Blind Phase 2 Clinical Trial—Phase 3 Study Next

HuvePharma Reports Ivermectin Helps Fight Against COVID-19 in Randomized, Controlled, Double-Blind Phase 2 Clinical Trial—Phase 3 Study Next

HuvePharma, a Bulgarian pharmaceutical company, reported on the results of its randomized, double-blind, placebo-controlled Phase2 clinical trial investigating its ivermectin-based product called Huvemek.® The sponsor revealed that the study led to positive results supporting the company to make substantial investment in a Phase 3 clinical trial. This study, reported on recently by TrialSite, showcases yet another study—over 40 now—where the great majority evidence general efficacy and safety when administered in individuals diagnosed with positive COVID-19. Some research-based groups such as BIRD believe the drug is ready now for emergency use authorization. Regardless, Huvepharma completed a Phase 2 clinical trial demonstrating that the drug not only accelerates clearance of the virus (by the third or fourth day after the onset of intake) to significant improvement in patient’s clinical condition as measured by the World Health Organization (WHO) scale. The drug also appears to have anti-inflammatory effects that may offer additional benefit to patients infected with SARS-CoV-2, the virus behind COVID-19.

The Results

TrialSite recently reported on this study however w...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee